A study for a 92 year old woman who takes Letairis - from FDA reports


Summary

984 females aged 92 (±5) who take the same drug are studied. This is a personalized study for a 92 year old female patient who has Pulmonary Hypertension. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>


On Sep, 10, 2017

984 females aged 92 (±5) who take Letairis are studied.


Number of reports submitted per year:

Letairis for a 92-year old woman.

Information of the patient in this study:

  • Age: 92
  • Gender: female
  • Conditions: Pulmonary Hypertension
  • Drugs taken:
    • Letairis (ambrisentan)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Shortness Of Breath: 117 (11.89% of females aged 92 (±5) who take the drug)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common side effects over time

< 1 month:
  • breathing difficulty
  • fatigue
  • oedema peripheral
  • swelling
  • dizziness
  • appetite - decreased
  • oedema
  • nausea
  • death
  • nasal congestion
1 - 6 months:
  • breathing difficulty
  • oedema
  • death
  • fluid retention
  • oedema peripheral
  • fatigue
  • dizziness
  • headache
  • nasal congestion
  • drug ineffective
6 - 12 months:
  • death
  • broken bone
  • drug ineffective
  • breathing difficulty
  • dementia
  • itching
  • acute respiratory failure
  • hypersensitivity
  • rashes
  • feeling abnormal
1 - 2 years:
  • death
  • anaemia
  • haematemesis
  • back pain
  • sinus disorder
  • breathing difficulty
  • abdominal discomfort
  • gastric ulcer
  • swelling
  • renal impairment
2 - 5 years:
  • death
  • cardiac failure congestive
  • swelling
  • peripheral swelling
  • disease progression
  • hearing loss
  • hypotension
  • right ventricular failure
  • amputation
  • confusional state
5 - 10 years:
  • death
  • fluid retention
  • fatigue
  • breathing difficulty
  • memory loss
  • chronic obstructive pulmonary disease
  • fall
  • intestinal obstruction
  • ruptured cerebral aneurysm
10+ years:
n/a
not specified:
  • breathing difficulty
  • death
  • pneumonia
  • fall
  • oedema
  • oedema peripheral
  • dizziness
  • malaise
  • peripheral swelling
  • nasal congestion

Top conditions involved for these people *:

  • Systemic Sclerosis (scleroderma) (22 people, 2.24%)
  • Cor Pulmonale Chronic (17 people, 1.73%)
  • Idiopathic Pulmonary Fibrosis (12 people, 1.22%)
  • Chronic Obstructive Pulmonary Disease (12 people, 1.22%)
  • Interstitial Lung Disease (6 people, 0.61%)

Top co-used drugs for these people *:

  • Revatio (99 people, 10.06%)
  • Coumadin (68 people, 6.91%)
  • Adcirca (64 people, 6.50%)
  • Lasix (48 people, 4.88%)
  • Tyvaso (36 people, 3.66%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

You can also:

Expand the study to include reports from both FDA and eHealthMe

Expand this study to include FDA and eHealthMe reports

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:

Related studies:

Can you answer these questions?

More questions for: Letairis, Shortness of breath, Pulmonary hypertension

You may be interested in these reviews

More reviews for: Letairis, Shortness of breath, Pulmonary hypertension